Physiomics shareholders back investor-led board overhaul at AIM-listed modelling firm

Physiomics ( (GB:PYC) ) just unveiled an update.

Physiomics plc has undergone a significant boardroom shake-up after shareholders at a requisitioned general meeting backed all resolutions, installing three new directors and removing four incumbent board members. Entrepreneur and major shareholder Michael Whitlow joins as executive director, capital markets veteran Nicholas Tulloch becomes non-executive chair, and chartered accountant Ian Bagnall is appointed non-executive director.

Outgoing directors Jim Millen, Shalabh Kumar, Tim Corn and Peter Sargent have been removed from the board with immediate effect, although Sargent will remain as CEO in a non-board capacity until 29 May 2026 to support an orderly handover. The changes, passed with roughly 78% of votes cast in favour, hand effective control to the new investor-backed team, with Whitlow and Bagnall together owning more than 15% of the shares, signalling a likely shift in strategic direction and governance at the drug development analytics firm.

Spark’s Take on PYC Stock

According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses and persistent cash burn), partially offset by a low-leverage balance sheet and some improvement in price trend. Valuation is constrained by negative earnings and lack of dividend support.

To see Spark’s full report on PYC stock, click here.

More about Physiomics

Physiomics plc is an AIM-listed mathematical modelling, data science and biostatistics specialist that supports biotech and pharmaceutical clients in developing new therapeutics and personalised medicine. Combining modelling and simulation, bioinformatics and its proprietary Virtual Tumour technology, the company helps streamline drug development from discovery through clinical trials, and counts Merck KGaA, Astellas and Cancer Research UK among its clients.

The Oxford-based group has delivered over 140 commercial projects covering more than 125 drug targets, positioning itself as a niche partner for de-risking R&D decisions in oncology and other therapy areas. By integrating disparate datasets into bespoke computational models, Physiomics aims to optimise study design and improve the probability of success in early- and late-stage development for its global biotech and pharma customer base.

Average Trading Volume: 8,273,103

Technical Sentiment Signal: Sell

Current Market Cap: £2.27M

Learn more about PYC stock on TipRanks’ Stock Analysis page.